【摘要】：目的探討埃索美拉唑鎂治療幽門螺桿菌(HP)陽性胃十二指腸炎的臨床療效及安全性。方法 54例HP陽性胃十二指腸炎患者隨機(jī)分為對照組及試驗(yàn)組各27例;對照組給予克拉霉素緩釋片0.5 g+阿莫西林克拉維酸鉀片562.5 mg+奧美拉唑腸溶片20 mg,2次/d,口服;試驗(yàn)組給予克拉霉素緩釋片0.5 g+阿莫西林克拉維酸鉀片562.5 mg+埃索美拉唑鎂腸溶片20 mg,2次/d,口服。比較兩組患者治療前后血清胃蛋白酶原(PG)Ⅰ、PGⅡ、PGⅠ/PGⅡ水平、治療有效率及安全性。結(jié)果治療后,與對照組比較,試驗(yàn)組患者血清PGⅠ、PGⅡ水平較低,PGⅠ/PGⅡ水平較高,差異顯著(P0.05)。試驗(yàn)組的治療有效率顯著高于對照組(P0.05)。兩組患者不良反應(yīng)發(fā)生率無明顯差異(P0.05)。結(jié)論埃索美拉唑鎂能顯著降低HP陽性胃十二指腸炎患者血清胃PGⅠ、PGⅡ水平,提高PGⅠ/PGⅡ水平,有效根除HP。
[Abstract]:Objective to investigate the efficacy and safety of esomeprazole magnesium in the treatment of Helicobacter pylori (HP) positive gastroduodenitis. Methods Fifty-four patients with HP positive gastroduodenitis were randomly divided into control group (n = 27) and experimental group (n = 27). The control group was treated with clarithromycin sustained release tablet 0.5 g amoxicillin clavulanate potassium tablet 562.5 mg omeprazole enteric-coated tablet 20 mg / d. The experimental group was given clarithromycin sustained release tablet 0.5 g amoxicillin clavulanate potassium tablet 562.5 mg esomeprazole magnesium enteric-coated tablet 20 mg / d. The serum levels of pepsinogen (PG) 鈪，

本文編號：2155558